Soluble FGFR3 Decoy Receptor for Achondroplasia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for achondroplasia and other FGFR3-related skeletal growth retardation disorders are invasive, ineffective, and lack a cure, with existing therapies only alleviating symptoms and not addressing the underlying bone growth issues effectively.
Innovation Solution
Administration of a recombinant soluble Fibroblast Growth Factor Receptor 3 (sFGFR3) polypeptide as a decoy receptor to inhibit FGFR3 signaling, promoting normal skeletal growth by binding to FGFs and preventing their interaction with the mutant FGFR3 receptor, thereby restoring bone growth and reducing complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (orthopedic surgeries, growth hormone therapy) are used, then some complications are alleviated, but the treatments are invasive, painful, and do not address the underlying bone growth issues
Solution Approach 1:
The patent uses soluble FGFR3 (sFGFR3) as a decoy receptor that acts as an intermediary to bind FGF ligands in the extracellular compartment, preventing them from activating the mutant FGFR3 on cell surfaces. This mediator approach blocks the harmful signaling pathway without requiring invasive surgical procedures or hormone injections, directly addressing the underlying molecular cause of the disorder.
2Length of moving object
If growth hormone therapy is used, then body height increases through periodic injections, but growth ceases when injections are stopped and the therapy does not cure the underlying condition
Solution Approach 1:
The patent applies preliminary action by blocking the pathological FGFR3 signaling pathway before it can inhibit bone growth. By administering sFGFR3 decoy receptors that pre-bind FGF ligands, the treatment prevents the mutant receptor from initiating its inhibitory signaling cascade, thereby allowing normal bone growth to proceed without requiring continuous external stimulation like growth hormone injections.
3Length of moving object
If leg lengthening surgery is performed, then limb length is increased, but the procedure inflicts great pain and does not restore normal bone development
Solution Approach 1:
The patent converts the harmful effect of mutant FGFR3 overactivity into a beneficial outcome by using the same receptor's binding capability against it. The sFGFR3 decoy receptors exploit the FGF-receptor binding mechanism to sequester FGF ligands away from the mutant receptors, thereby converting the pathological signaling pathway into a therapeutic mechanism that restores normal bone growth without surgical intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment effectively restores normal skeletal growth, reduces the severity of complications, and is shown to be safe with no evidence of toxicity, offering a promising therapeutic approach for achondroplasia and related disorders by enhancing bone growth and maturation in a dose-dependent manner.
Implementation Method 1
targeting mutant FGFR3 and its downstream signaling... a novel peptide inhibiting FGFR3 signaling... binding to FGFs and preventing their interaction with the mutant FGFR3 receptor
Data Source
AI summary
The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.